Benzyloxazolidine-2,4-diones as potent hypoglycemic agents.
A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.
Dow
R L
RL
Central Research Division, Pfizer Incorporated, Groton, Connecticut 06340.
Bechle
B M
BM
Chou
T T
TT
Clark
D A
DA
Hulin
B
B
Stevenson
R W
RW
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D051379:Mice; D008820:Mice, Obese; D010080:Oxazoles / Q000138:chemical synthesis* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010080:Oxazoles